Business Context and Reporting Period
This Form 8-K was filed by Artelo Biosciences, Inc. on November 17, 2020. The report addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on listing compliance status rather than financial performance.
Material Changes
- Delisting Notice: The Company received written notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Compliance Period: The Company has been granted an initial period of 180 calendar days (until May 17, 2021) to regain compliance.
- Compliance Criteria: To regain compliance, the closing bid price of the common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
Outlook, Risks, and Management Commentary
- Immediate Impact: The notification has no immediate effect on the listing of the Company's common stock on The Nasdaq Capital Market.
- Extension Possibility: If compliance is not met by May 17, 2021, Nasdaq may grant a second 180-day period. Qualification requires meeting the market value of publicly held shares and other initial listing standards, excluding the minimum bid price.
- Remedial Actions: The Company may implement a reverse stock split to cure the deficiency if necessary.
- Delisting Risk: Failure to regain compliance within allotted periods could lead to delisting, subject to an appeal to a Nasdaq hearings panel.
- Management Plan: The Company intends to monitor the closing bid price and consider available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of ARTL common stock relative to the $1.00 threshold.
- Monitor the company's stock price for ten consecutive business days to assess compliance progress.
- Watch for announcements regarding a potential reverse stock split.
- Review the company's market value of publicly held shares to determine eligibility for a second compliance period if needed.
- Check for any future 8-K filings regarding the outcome of the compliance period or delisting appeals.